Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Molecular Templates, Inc. | v315311_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2012
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-32979 | 94-3409596 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip Code)
(650) 474-8200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On June 4, 2012, Threshold Pharmaceuticals, Inc. issued a press release announcing details from two clinical posters featured at the American Society of Clinical Oncology Meeting in Chicago: a trial-in-progress presentation summarizing the design and status of the ongoing international Phase 3 study comparing TH-302 in combination with doxorubicin to single agent doxorubicin in patients with first-line soft tissue sarcoma and a presentation of updated results from the Phase 1 study of TH-302 in patients with advanced leukemias conducted at the MD Anderson Cancer Center in Houston, Texas. The press release is attached as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release dated June 4, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| THRESHOLD PHARMACEUTICALS, INC. | ||
| By: | /s/ Joel A. Fernandes | |
| Joel A. Fernandes
Vice President, Finance and Controller | ||
Date: June 5, 2012
Exhibit Index
| Exhibit No. | Description | |
| Exhibit 99.1 | Press release dated June 4, 2012. |